NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 230)
Posted On: 07/02/2021 3:41:27 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer.” The goal is to bring researchers the next level of tools for hard-to-treat diseases, helping them avoid early mistakes that contribute to the already exorbitant cost of drug development. “The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer.” The goal is to bring researchers the next level of tools for hard-to-treat diseases, helping them avoid early mistakes that contribute to the already exorbitant cost of drug development. “The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼